In response to feedback from users of its human regulatory website, the EMA has simplified the main navigation menu. The initial links correspond to the key medicinal product lifecycle stages:
Selecting one of these links will take the user both to an overview for the chosen key stage and also to a sub-menu of other active links relevant to the chosen stage.
Let us consider some stress management ideas, forwarded to me by a friend!
A young lady (but if you like, it could have been a young man!) confidently walked around the room while leading and explaining stress management to an audience with a raised glass of water. Everyone knew she was going to ask the ultimate question, “half empty or half full?”
She fooled them all! “How heavy is this glass of water?” she inquired with a smile.
Answers called out ranged from 8 oz. to 20 oz.
She replied, “The absolute weight doesn’t matter. It depends on how long I hold it. If I hold it for a minute, that’s not a problem. If I hold it for an hour, I’ll have an ache in my right arm.
If I hold it for a day, you’ll have to call an Ambulance. In each case it’s the same weight, but the longer I hold it, the heavier it becomes.”
She continued, “and that’s the way it is with stress. If we carry our burdens all the time, sooner or later, as the burden becomes increasingly heavy, we won’t be able to carry on.”
“As with the glass of water, you have to put it down for a while and rest before holding it again. When we’re refreshed, we can carry on with the burden – holding stress longer and better each time practised.”
“So, as early in the evening as you can, put all your burdens down. Don’t carry them through the evening and into the night. Pick them up tomorrow.”
- Accept the fact that some days you’re the pigeon, and some days you’re the statue!
- Always keep your words soft and sweet, just in case you have to eat them.
- Always read stuff that will make you look good if you die in the middle of it.
- Drive carefully… It’s not only cars that can be recalled by their Maker.
- If you can’t be kind, at least have the decency to be vague.
- If you lend someone £20 and never see that person again, it was probably worth it.
- It may be that your sole purpose in life is simply to serve as a warning to others.
- Never buy a car you can’t push.
- Never put both feet in your mouth at the same time, because then you won’t have a leg to stand on.
- Nobody cares if you can’t dance well. Just get up and dance.
- Since it’s the early worm that gets eaten by the bird, sleep late.
- The 2nd mouse gets the cheese.
- When everything’s coming your way, you’re in the wrong lane.
- Birthdays are good for you. The more you have, the longer you live.
- Some mistakes are too much fun to make only once.
- We could learn a lot from crayons. Some are sharp, some are pretty and some are dull. Some have weird names and all are different colours, but they all have to live in the same box.
- A truly happy person is one who can enjoy the scenery on a detour.
- Have an awesome day and know that someone has thought about you today.
AND MOST IMPORTANTLY
19. Save the earth….. It’s the only planet with chocolate! I THINK !!!!
The EDQM (or in full, the European Directorate for the Quality of Medicines & HealthCare) maintains the Standard Terms Database, which holds the official European list of terms and definitions for describing Pharmaceutical Dose Forms, Routes and Methods of Administration, Containers, Closures and Administration Devices.
Standard Terms are to be used in the Marketing Authorisation Application, the Summary of Product Characteristics (SmPC), and in labelling and electronic communications.
They are currently provided in the Database in 33 languages from around the world: Albanian, Bosnian, Bulgarian, Chinese, Croatian, Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Greek, Hungarian, Icelandic, Italian, Kazakh, Latvian, Lithuanian, Macedonian, Maltese, Norwegian, Polish, Portuguese, Romanian, Serbian, Slovak, Slovene, Spanish, Swedish, Turkish and Ukrainian.
The Database content includes combinations of terms, for example to describe where two or more items are packaged together, or where a pharmaceutical dose form and a container are described using a single term. The Database also contains patient-friendly terms, which are generally shorter terms that, where justified and authorised by the competent authority, may be used on certain labels where space is limited.
Originally a printed publication, from 1 January 2016, all approved Standard Terms and their definitions and translations can be found online in the Standard Terms database maintained by EDQM.
The database requires a registration, but is open and free for all users. The registration takes place on the EQDM website. If you do not already have an account you can set one up for free. Start by searching for https://www.edqm.eu/register/ or use your browser to search for “EDQM HelpDesk Publications Registration”.
Once you are registered select the free access link for the Standard Terms Database, complete details as necessary and your password will be emailed to you by the EDQM.
A U.S. judge on Friday barred the U.S. Food and Drug Administration from stopping Irish drugmaker Amarin Corp from promoting its fish oil drug for off-label uses, saying the company is protected by the First Amendment.
The pharmaceutical industry has been watching this case because it is one of the first to raise a First Amendment argument in defense of promoting drugs for uses the FDA has not approved. Shares of Amarin rose 12 percent on Nasdaq.
The order by U.S. District Judge Paul Engelmayer in Manhattan means Amarin can promote its Vascepa pill to doctors for off-label use as long as it does so truthfully.
Release and/or Implementation of delegated acts under the FMD legislation by the European Commission are delayed until later this year
An API manufacturer (“Mumbai Pharma Substances”) based in India wants to export an active substance from Mumbai to
(i) Kenya and to
What steps should Mumbai Pharma Substances take / have taken to ensure that these export sales proceed smoothly in the context of recent regulatory changes in the European Union?
A drug product (dosage form) manufacturer based in France wants to purchase an active substance from Mumbai Pharma Substances and take delivery at the French factory site. Two delivery routes are being considered:
(i) air freight by direct flight from Mumbai to France, followed by secure storage at the French airport pending road transport with direct delivery to the French factory,
(ii ) air freight by direct flight from Mumbai to the UK, with secure storage first at the UK airport and then at a MHRA-licensed UK facility pending onward transport by road directly to the French factory.
What issues come to your mind concerning compliance with the recent regulatory changes in the European Union?
A Marketing Authorisation Holder in the UK has approval to manufacture its generic product in India and in Germany, for the purpose of supplying the UK market.
Compare and contrast the regulatory issues that affect each of these two sources, in the context of recent regulatory changes in the European Union.
Does your Company source APIs from outside the EU (i.e. from a third country)? When it comes to sourcing APIs what is meant by listed and non-listed third countries? Where can I find the list and which countries are listed?
What is a written confirmation?
What is an Atypical Active Substance?
My company’s risk assessment against the use of the excipient lactose has concluded that this is high risk.
As part of the company’s risk mitigation procedure, I need to carry out an audit of the manufacture of this material. Which audit standard can I use for this which will be acceptable to the inspector?
The company uses sodium benzoate as a preservative in one of the oral liquid products which we manufacture. As our requirement is only 15 kg per year we source this excipient via a UK distributor. However as this distributor refuses to identify the actual manufacturer I am unable to perform the required risk assessment on this material. What should be my actions in this case?
My Company uses the same grade propylene glycol as an excipient in pharmaceutical products which are used both topically and parenterally.
The risk assessment concludes that this excipient is both ‘low risk’ and ‘high risk’ simultaneously. How to I approach this with the supplier?
I am importing from South Korea a cellulosic material which meets the requirements of the PhEur and using it as the active component of an ophthalmic product for the treatment of ‘dry eye’. The manufacturer will not guarantee that the material is manufactured in accordance with GMPs for active pharmaceutical ingredients, but does certify that it is manufactured in accordance with appropriate excipient GMPs. What are my options?
“What are the main changes with the directive for the wholesale supply chain?”
“What policy do you support with regard to the checking of goods to ensure no counterfeits enter the UK wholesale supply chain?”
“What principles do you support on the product pack and coding for the unique identifier?”
“What are the significant challenges and cost implications for wholesale suppliers in adopting the new legislation?”
My company only purchases a small quantity of API each year from broker based in the UK who in turn purchases the API from an Indian API manufacturer. Do I need to audit both the broker and the manufacturer?
The API manufacturer has already been inspected by both the FDA & Danish authorities; do I still need to do an on-site audit?
“The API company in India will only allow a one day audit; what are my options?”
“As a QP what do I need to know about my API suppliers before I certify that the drug product is suitable for release?”
“Will all generic medicines end up needing to carry the tracking device and tamper evident seal?”
“Can a track & trace system that relies on an EU wide IT system ever work quickly enough in practice?”
Is a UK only system for track & trace possible?
Please use the links on our site at http://www.pharmaqmtraining.eu/brochures/falsified_medicines.html to learn more about the Course, which is confirmed to proceed in London on Thursday 27th February 2014. There is information available on the main subject areas of the training, on the excellent panel of speakers and on the delegate package, which is priced to be attractive. You will find it easy to make your booking and you should definitely not delay if you want to secure a place. Delegate numbers will have to be finalised soon, so act now to avoid disappointment.
We look forward to meeting you and to sharing a lively programme with good sessions dealing with your questions.
There are potential changes under consideration as described here . The article also contains a link to a clear review of the current situation. Hope this is of use.
A 1-day non-residential course on
27 February 2014
at the Royal Society of Chemistry,
Burlington House, Piccadilly, London W1J 0BA, United Kingdom
This Course gives you another opportunity to have your questions answered about the ‘Falsified Medicines Directive’ (FMD), which is one of the most significant pieces of pharmaceutical legislation to arrive for many years!
The urgent intention of the FMD is to protect European patients from receiving falsified medicines.
Outlined below are selected reasons why attendance at the Course might be important to position you as an up-to-date Regulatory or GMP Expert (or other person) in a role which requires your action, advice or other input into decisions being made for your company’s benefit.
If you are involved with the production of active substances you will need to take serious account of this new legislation and the various means by which its Articles have been, are being and will continue to be applied in the daily life of the global pharmaceutical industry.
In addition and not surprisingly there are many legal changes taking effect that impact on excipients, also intended to protect the public from falsified medicines.
Most EU companies, aiming to ensure compliance with the new law, face the prospect of carrying out a lot more international and European work. However, it is not just European companies that are affected. This EU legislation has major impacts on a substantial number of parties operating outside the ‘European Community’.
Companies and people involved in the distribution or other movement of pharmaceutical materials from one place to another or those who use, manage, supervise, regulate or give advice about these materials, to make intermediates or finished medicines, face new requirements. That is likely to mean that there are new activities for you to know about and new actions to take.
Unless you are already sure that you understand fully the changes being required, you would be wise to book your place on our new Course. We will deliver up-to-date knowledge and understanding to delegates to help them and therefore their companies counteract the menace of falsified medicines.
Please use the links on our site to learn more about the Course. There is information available on the main subject areas of the training, on the excellent panel of speakers and on the delegate package, which is priced to be attractive. You will find it easy to make your booking and you should not delay if you want to secure a place.
We look forward to meeting you and to sharing a lively programme with good sessions dealing with your questions.
In my previous post I emphasised how attendance at the Pharmaqmtraining.eu FMD course might enhance your performance as a ‘Regulatory or GMP’ Company Expert or other person such as a Freelance Consultant acting as an adviser to a pharmaceutical company or ancillary business.
In this post I want to provide you with information about the Team that will provide the training so that you can appreciate the extraordinary collective experience available to delegates and also see with whom you will have some networking opportunities on the day.
Chairman: Derek Calam is a Visiting Professor of Pharmaceutical Sciences, University of Strathclyde, a Member of the WHO Expert Panels for both Pharmaceuticals and Biologicals and Chairman of the WHO Committee responsible for allocating names to medical substances on a global basis. He is a UK-nominated Expert at the European Medicines Evaluation Agency (EMEA) in London, and much more.
For over 25 years Derek has been advising the UK Regulatory Authority on quality matters concerning Chemistry, Pharmacy & Standards and Biological and Biotechnological Medicines. He has also served as Chairman of the European Pharmacopoeia Commission, of the British Pharmacopoeia Commission and of the EDQM Steering Committee for Certification, Strasbourg.
Speakers: Paul Fleming is Technical Director of the British Generic Manufacturers Association (BGMA) which represents the views of the generic medicines industry in UK and has close and regular discussions with MHRA, other parts of the Department of Health and the NHS. At a European level, Paul is a key Member of the Regulatory Committee of the European Generic Medicines Association, EGA. In both these roles, he is involved in the development and implementation of new regulatory guidance.
Paul has spent many years working for pharmaceutical generic companies in Europe at senior board level in roles covering drug regulation, pharmacovigilance and formulation development. Previously, for six years he was a Pharmaceutical Assessor at the MHRA.
Geoff Mellor is Technical Director of the British Association of Pharmaceutical Wholesalers (BAPW) which represents full-line pharmaceutical wholesalers in the UK. BAPW is a Member of the Brussels based European Association of Pharmaceutical Full-line Wholesalers, the GIRP.
Geoff leads for the BAPW on all technical, regulatory and liaison aspects and is the Association’s primary contact with the MHRA. He is also a member of the GIRP Technical Committee, which covers aspects of health policy developments within the European Union.
Carl Mroz is the Director of Global Regulatory Affairs, EMEA for Colorcon Limited in the UK. He is an active member of the International Pharmaceutical Excipients Council (IPEC) Europe, as the Chair of the Quality and Regulatory Affairs Committee and is also a Member of the European Pharmacopoeia Working Party on Functionality Related Characteristics, a Member of the British Pharmacopoeia Working Party on Excipients and the Panel of Experts on Inorganic Chemicals.
Carl is a past Chair of IPEC Europe and has been involved with the pharmaceutical industry for over 30 years in a variety of roles including Production, Quality Control, Regulatory Affairs and Quality Assurance. He is an active international lecturer with particular expertise on compounded excipients used in conjunction with solid oral dosage forms.
Steve Porter is a highly experienced Quality Professional with over 35 years’ service in the Pharmaceutical Industry. He is currently a Company Director at Steve Porter Pharma Consulting providing services in internal and supplier auditing, quality system design and enhancement, regulatory inspection preparations and remedial actions, design and delivery of training courses, supply chain design and evaluation, and QP services. He is a Fellow of the Royal Society of Chemistry.
Steve has extensive auditing experience in the US, Europe and Asia (China, India, Japan). He has also served as a Board Member of IPEC Europe. He is an experienced International lecturer.
Until recently he was QA Director (Compliance), Global External Sourcing at Astra Zeneca. His many duties there included involvement with the company’s preparations for compliance with the Falsified Medicines Directive.
Mike Robertson designs our courses and he has created over 100 public conferences for other conference providers. He is a Visiting Lecturer at King’s College, University of London and an experienced International lecturer.
Mike is an experienced freelance Pharmaceutical Regulatory and GMP Consultant at Pharmaceutical Quality Matters, a Quality Assessor on the WHO Prequalification Programme (Geneva – Copenhagen) and a scientific author on CMC and other subjects.
After more than 11 years in the pharmaceutical industry in QC & R&D operations Mike became eligible to register as a QP and then for 20 years, he worked at the Medicines Control Agency (MCA), now the MHRA in London, first as a Pre-Clinical (Nonclinical) Assessor and then as a Pharmaceutical Assessor. He has also served on various bodies associated with the British Pharmacopoeia Commission, the EDQM and the European Pharmacopoeia Commission.
In total, a real wealth of expertise and experience!
Are you and your company up-to-date with the many developments arising from the FMD?
Look out for the next date for this Course and be sure to book your place quickly to avoid disappointment. Places will be limited!
You can register your interest by clicking here. Don’t be disappointed!